65,437 trials
Persistent Asthma
Primary: Participants With Treatment-Emergent Adverse Experiences (TEAE) During the Treatment Period — 85; 29; 83; 29 Participants
Pain
Primary: Pain After Placement of Laminaria (100 mm Visual Analog Scale) — 13; 54 units on a scale (100 mm VAS) — p=0.01
Otic Eczema
Primary: Analysis of the Itching Change at the End of Treatment. — -1.63; -1.25 units on a scale
Breast Cancer
Primary: Percentage of Participants Demonstrating a Decrease in the Growth Factor Signature (GFS) — 28.6; 17.6 Percentage of participants
Immune System Diseases
Primary: Change From Baseline in T-cell Response to the VZV Vaccine in the Frail Elderly — 50.17; 78.17; 83.22; 120.56 Spot Forming Units per 10^6 PBMC
Ornithine Transcarbamylase Deficiency
Primary: Concentration of Glutamine and Myoinositol — 2.61; 1.66; 2.23; 2.69 mM — p=0.001
Sarcoma, Soft Tissue
Primary: Progression-free Survival (PFS) — 6.6; 4.1 Month — p=0.0615
Glaucoma
Primary: Intraocular Pressure (IOP) Change — -3.0; -6.2; -5.2 mmHg
Secondary Hyperparathyroidism in Patients With ESRD on Hemodialysis
Primary: Cumulative Excretion of Radioactivity — 35.29; 24.26; 0.75; 2.40 Percentage of administered dose
Posttraumatic Stress Disorder
Primary: Differential Skin Conductance Response (SCR) During the First Two Extinction Trials — 0.15; 0.00 micro-Siemens (square rooted) — p=0.28
Burnout · Quality of Care
Primary: Maslach Burnout Inventory (MBI): Emotional Exhaustion — 2.3; 2.7; 2.3; 2.7 units on a scale — p=0.80
Mental Disorders
Primary: The Number of Individuals Diagnosed With Antisocial Personality Disorder in Rochefort Prison With Aberrant Driving Behaviors. — 9 participants
Colon Adenoma
Primary: Adenoma Detection Rate (All Indications) — 264; 271 Participants
Chronic Postoperative Pain
Primary: Pain Score on Moving at 6 Weeks — 0; 1.5 units on a scale — p=0.33
Glaucoma
Primary: Change in Intraocular Pressure (IOP) (ΔIOP) Three Months After Trabeculectomy in Comparison to the Mean Preoperative IOP — 8.30; 8.12 mmHg